Two recent NICE Technology Appraisals have been recently published online; NICE is not recommending belimumab for lupus and is recommending dapagliflozin for diabetes. The NICE Decision Support Unit, based in
HEDS, contributed reports to both appraisals. Visit the
DSU website for more details.
